Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - carboplatin injection bp is indicated for the treatment of ovarian cancer of epithelial origin in first line therapy, and in second line therapy after other treatments have failed.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - carboplatin - solution for infusion - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - carboplatin - solution for infusion - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - carboplatin - solution for infusion - 10mg/1ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare polska sp. z o.o. - carboplatin - concentrate for solution for infusion - 10mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare polska sp. z o.o. - carboplatin - concentrate for solution for infusion - 10mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare polska sp. z o.o. - carboplatin - concentrate for solution for infusion - 10mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection - excipient ingredients: water for injections - indications for uk market - treatment of some types of lung cancer and ovarian cancer. indications for france market - it is recommended for the treatment of certain diseases of the ovaries, bronchi and aerodigestive pathways. indications for greece and cyprus market - carboplatin is a second-generation cisplatin derivative which has shown to possess antitumor activity against a number of malignancies. the drug is indicated for the treatment of the following solid tumours: ? ? advanced ovarian carcinoma of epithelial origin. ? ? small cell lung cancer. ? ? non-small cell lung cancer. ? ? epidermoid head and neck cancer. ? ? transitional cell cancer of the bladder (in combination with other cytostatic agents). ? ? cervical carcinoma in case of failure or unacceptable toxicity of cisplatin treatment or when the doctor considers that it cannot be tolerated.

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - carboplatin - concentrate for soln for inf - 10 mg/ml - carboplatin

Philippines - English - FDA (Food And Drug Administration)

united laboratories, inc.; distributor: united laboratories, inc. - carboplatin - solution for iv infusion - 10 mg/ml (450 mg/ 45 ml)